anti-TL1A monoclonal antibody, medium dose Clinical Trials
2 recruitingBiologic
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis (UC)
Biocad198 enrolled20 locationsNCT07080034
Recruiting
Phase 2
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
Crohn's Disease (CD)
Biocad204 enrolled20 locationsNCT07078994